One less potential competitor for Botox

Johnson and Johnson (JNJ) discontinues its development of PurTox, a neurotoxin intended to compete with Allergan's (AGN) $2B anti-wrinkle blockbuster.

The company acquired the rights to the drug in 2009 with its buy of Mentor Corp.

The move will result in the loss of a small number of U.S.-based jobs.

From other sites
Comments (1)
  • User 22591111
    , contributor
    Comment (1) | Send Message
    when will JNJ get the FDA nod on this "Botox"?
    14 Apr 2014, 09:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs